163 related articles for article (PubMed ID: 17909018)
21. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
Sandhu C; Peehl DM; Slingerland J
Cancer Res; 2000 May; 60(10):2616-22. PubMed ID: 10825132
[TBL] [Abstract][Full Text] [Related]
22. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence.
Brookes S; Rowe J; Ruas M; Llanos S; Clark PA; Lomax M; James MC; Vatcheva R; Bates S; Vousden KH; Parry D; Gruis N; Smit N; Bergman W; Peters G
EMBO J; 2002 Jun; 21(12):2936-45. PubMed ID: 12065407
[TBL] [Abstract][Full Text] [Related]
23. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma.
Liu L; Lassam NJ; Slingerland JM; Bailey D; Cole D; Jenkins R; Hogg D
Oncogene; 1995 Jul; 11(2):405-12. PubMed ID: 7624155
[TBL] [Abstract][Full Text] [Related]
24. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.
Petronzelli F; Sollima D; Coppola G; Martini-Neri ME; Neri G; Genuardi M
Genes Chromosomes Cancer; 2001 Aug; 31(4):398-401. PubMed ID: 11433531
[TBL] [Abstract][Full Text] [Related]
25. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
26. Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.
Scaini MC; Rossi E; de Siqueira Torres PL; Zullato D; Callegaro M; Casella C; Quaggio M; Agata S; Malacrida S; Chiarion-Sileni V; Vecchiato A; Alaibac M; Montagna M; Mann GJ; Menin C; D'Andrea E
Mutat Res; 2009 Dec; 671(1-2):26-32. PubMed ID: 19712690
[TBL] [Abstract][Full Text] [Related]
27. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.
Liu L; Dilworth D; Gao L; Monzon J; Summers A; Lassam N; Hogg D
Nat Genet; 1999 Jan; 21(1):128-32. PubMed ID: 9916806
[TBL] [Abstract][Full Text] [Related]
28. Mutations associated with familial melanoma impair p16INK4 function.
Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
[TBL] [Abstract][Full Text] [Related]
29. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.
Ruas M; Brookes S; McDonald NQ; Peters G
Oncogene; 1999 Sep; 18(39):5423-34. PubMed ID: 10498896
[TBL] [Abstract][Full Text] [Related]
30. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
31. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
[TBL] [Abstract][Full Text] [Related]
32. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
[TBL] [Abstract][Full Text] [Related]
33. Expression of p16INK4A variants in senescent human fibroblasts independent of protein phosphorylation.
Weebadda WK; Jackson TJ; Lin AW
J Cell Biochem; 2005 Apr; 94(6):1135-47. PubMed ID: 15668906
[TBL] [Abstract][Full Text] [Related]
34. In silico analysis of structural and functional consequences in p16INK4A by deleterious nsSNPs associated CDKN2A gene in malignant melanoma.
Rajasekaran R; Priya Doss CG; Sudandiradoss C; Ramanathan K; Sethumadhavan R
Biochimie; 2008 Oct; 90(10):1523-9. PubMed ID: 18573309
[TBL] [Abstract][Full Text] [Related]
35. Reducing CDK4/6-p16(INK4a) interface. Computational alanine scanning of a peptide bound to CDK6 protein.
Villacañas O; Rubio-Martinez J
Proteins; 2006 Jun; 63(4):797-810. PubMed ID: 16508961
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
[TBL] [Abstract][Full Text] [Related]
37. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
38. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
39. Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization.
Munro J; Stott FJ; Vousden KH; Peters G; Parkinson EK
Cancer Res; 1999 Jun; 59(11):2516-21. PubMed ID: 10363964
[TBL] [Abstract][Full Text] [Related]
40. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
